- (+)-Muscarine chloride
- L-(+)-Muscarine chloride
- (+)-Tetrahydro-4b-hydroxy-N,N,N,5a-tetramethyl-2a-furanmethanaminium chloride
- (+)-(2S,4R,5S)-Tetrahydro-4-hydroxy-N,N,N,5-tetramethyl-2-furanmethanammonium chloride
White powder. Extremely hygroscopic.
Prototype muscarinic acetylcholine receptor agonist; active enantiomer.
Registry Numbers and Inventories.
22 36/37/39 45
Melting point, °C
180 - 181
Solubility in water
Hazards and Protection.
Compatible chemical-resistant gloves. Chemical safety goggles.
Government approved respirator.
Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area and wash spill site after material pickup is complete.
Stable at normal temperatures and pressures.
Carbon monoxide, Carbon dioxide, Nitrogen oxides.
Extinguish using Carbon dioxide, dry chemical powder, or appropriate foam. Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.
Non-combustible, substance itself does not burn but may decompose upon heating to produce corrosive and/or toxic fumes.
Contact with metals may evolve flammable hydrogen gas.
Fire may produce irritating, corrosive and/or toxic gases.
Onset is within 30 to 120 minutes. Symptoms are similar to cholinergic poisoning, including excessive perspiration, salivation and lacrimation, bradycardia miosis, blurred vision, abdominal pain, diarrhea hypotension and pulmonary congestion. This condition is often referred to as the PSL syndrome (perspiration salivation, lacrimation). Profuse sweating is the most useful clinical finding to distinguish between this group and general gastrointestinal irritant mushrooms Symptoms are usually short-lived, subsiding within two hours without treatment, but can persist 6 to 24 hours.
Excessive salivation, abdominal cramps, and vomiting followed by watery diarrhea are common findings.
Bronchospasm, wheezing, nasal discharge, and bronchorrhea may occur.
Contact with molten substance may cause severe burns to skin and eyes. See Inhalation.
Administer charcoal as a slurry (240 mL water/30 g charcoal). Usual dose: 25 to 100 g in adults/adolescents, 25 to 50 g in children (1 to 12 years), and 1 g/kg in infants less than 1 year old. Atropine should be administered if life-threatening cholinergic symptoms exist. A test dose of 1-2 mg intravenously is standard in an adult while 0.02 mg/kg is given in children. Poisoned patients will show no signs of atropinism and the atropine may be repeated as is necessary. End point of therapy is cessation of secretions, not just mydriasis.
If inhaled, remove to fresh air. If breathing becomes difficult, call a physician.
In case of skin contact, flush with copious amounts of water for at least 15 minutes. Remove contaminated clothing and shoes. Call a physician.
In case of contact with eyes, flush with copious amounts of water for at least 15 minutes. Assure adequate flushing by separating the eyelids with fingers. Call a physician.